XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.3
Long-Term Investments (Details) - Schedule of Long-Term Investment - USD ($)
Sep. 30, 2024
Dec. 31, 2023
Schedule of Long-Term Investment [Line Items]    
Non-marketable Cost Method Investments, net $ 816,160 $ 847,252
Equity Method Investments, net 2,333,904 2,527,740
Braingenesis Biotechnology Co., Ltd. [Member]    
Schedule of Long-Term Investment [Line Items]    
Non-marketable Cost Method Investments, net 6,948 7,213
Genepharm Biotech Corporation [Member]    
Schedule of Long-Term Investment [Line Items]    
Non-marketable Cost Method Investments, net 21,213 22,021
BioHopeKing Corporation [Member]    
Schedule of Long-Term Investment [Line Items]    
Non-marketable Cost Method Investments, net 787,999 818,018
ForSeeCon Corporation [Member]    
Schedule of Long-Term Investment [Line Items]    
Non-marketable Cost Method Investments, net
BioFirst Corporation [Member]    
Schedule of Long-Term Investment [Line Items]    
Equity Method Investments, net [1] 1,517,744 1,680,488
Rgene Corporation [Member]    
Schedule of Long-Term Investment [Line Items]    
Equity Method Investments, net [2]
[1] BioFirst Corporation (the “BioFirst”): The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments-Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of September 30, 2024 and December 31, 2023, the Company owns 18.68% and 18.68% common stock shares of BioFirst, respectively. The Company made a prepayment for equity investment in BioFirst to purchase additional shares to be issued by BioFirst in the aggregate amount of $2,688,578, recorded as prepayment for long-term investments as of December 31, 2022. On July 19, 2023, the Company successfully completed the registration process for this investment. The initial prepayment was $1,895,556, which is a portion of the prepayment as of December 31, 2022, and was converted into 994,450 shares of BioFirst stock. As of September 30, 2024, the amount of prepayment for long-term investments in BioFirst is $1,124,842.
[2] Rgene Corporation (the “Rgene”) Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and Chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to account for its equity investment as prescribed in ASC 323, Investments-Equity Method and Joint Ventures (“ASC 323”). Equity method adjustments include the Company’s proportionate share of investee’s income or loss and other adjustments required by the equity method. As of September 30, 2024 and December 31, 2023, the Company owns 26.65% and 26.65% Common Stock shares of Rgene, respectively.